Blockade of t lymphocyte down-regulation associated with ctla-4 signaling
CA 2239448 C · Owner: Leach, Dana R. · Inventors: Allison, James Patrick; Krummel, Matthew F.; Leach, Dana R.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
T cell activation in response to antigen is increased by the administration of binding agents that block CTLA-4 signaling. When CTLA-4 signaling is thus blocked, the T cell response to antigen is released from inhibition. Such an enhanced response is useful for the treatment of tumors chronic viral , infections, and as an adjuvant during immunization.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 4, 1996 and granted October 1, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 4, 2016.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 4, 2018.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.